This company listing is no longer active
Marrone Bio Innovations (0MB) Stock Overview
Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
0MB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
An Undervalued 3.3Moz Gold Project in Canada
Key takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read more
Marrone Bio Innovations, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.96 |
| 52 Week High | US$1.25 |
| 52 Week Low | US$0.49 |
| Beta | 0.36 |
| 1 Month Change | -7.21% |
| 3 Month Change | 14.20% |
| 1 Year Change | -18.22% |
| 3 Year Change | -24.94% |
| 5 Year Change | 2.88% |
| Change since IPO | -56.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0MB | DE Chemicals | DE Market | |
|---|---|---|---|
| 7D | 0.5% | -0.2% | 0.8% |
| 1Y | -18.2% | 10.5% | 8.3% |
Return vs Industry: 0MB exceeded the German Chemicals industry which returned -30.3% over the past year.
Return vs Market: 0MB exceeded the German Market which returned -25% over the past year.
Price Volatility
| 0MB volatility | |
|---|---|
| 0MB Average Weekly Movement | 12.9% |
| Chemicals Industry Average Movement | 5.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 13.7% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 0MB has not had significant price volatility in the past 3 months.
Volatility Over Time: 0MB's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 153 | Kevin Helash | www.marronebio.com |
Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health.
Marrone Bio Innovations, Inc. Fundamentals Summary
| 0MB fundamental statistics | |
|---|---|
| Market cap | €144.25m |
| Earnings (TTM) | -€20.70m |
| Revenue (TTM) | €43.97m |
Is 0MB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0MB income statement (TTM) | |
|---|---|
| Revenue | US$44.37m |
| Cost of Revenue | US$17.89m |
| Gross Profit | US$26.48m |
| Other Expenses | US$47.37m |
| Earnings | -US$20.89m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 59.69% |
| Net Profit Margin | -47.08% |
| Debt/Equity Ratio | 139.3% |
How did 0MB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/14 03:27 |
| End of Day Share Price | 2022/07/12 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Marrone Bio Innovations, Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathan Weinstein | Aegis Capital Corporation |
| Benjamin Kallo | Baird |
| Robert Burleson | Canaccord Genuity |